📊 BEATW Key Takeaways
Investment Thesis
HeartBeam is a pre-revenue or early-stage medical device company with severe financial distress, burning approximately $14-21M annually with minimal cash generation. The company's negative profitability metrics (-807% ROE, -360% ROA), combined with unsustainable cash burn rate relative to $4.4M cash reserves, presents existential viability concerns without immediate revenue inflection or capital raise.
BEATW Strengths
- Maintains adequate short-term liquidity with 1.90x current ratio and $4.4M cash position
- Zero long-term debt eliminates near-term refinancing risk and provides capital structure flexibility
- Medical device sector (surgical instruments) operates in growing market with recurring revenue potential if commercialization succeeds
BEATW Risks
- No revenue generation with approximately 6-months cash runway at current burn rate; imminent capital raise or insolvency risk
- Severe and deteriorating unit economics with -$21M net loss and -$14M operating cash flow indicating fundamental business model failure
- Minimal balance sheet ($5.8M assets) provides no cushion for development delays or clinical setbacks; high dilution risk for existing shareholders from necessary equity financing
Key Metrics to Watch
- Revenue initiation and gross margin sustainability upon commercialization
- Cash burn rate trend and runway to profitability timeline
- Shareholder dilution from capital raises and cumulative losses impact on equity base
BEATW Financial Metrics
💡 AI Analyst Insight
HeartBeam, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BEATW Profitability Ratios
BEATW vs Healthcare Sector
How HeartBeam, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BEATW Balance Sheet & Liquidity
BEATW 5-Year Financial Trend
5-Year Trend Summary: HeartBeam, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.73 indicates the company is currently unprofitable.
BEATW Growth Metrics (YoY)
BEATW Capital Allocation
BEATW SEC Filings
Access official SEC EDGAR filings for HeartBeam, Inc. (CIK: 0001779372)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BEATW
What is the AI rating for BEATW?
HeartBeam, Inc. (BEATW) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BEATW's key strengths?
Maintains adequate short-term liquidity with 1.90x current ratio and $4.4M cash position. Zero long-term debt eliminates near-term refinancing risk and provides capital structure flexibility.
What are the risks of investing in BEATW?
No revenue generation with approximately 6-months cash runway at current burn rate; imminent capital raise or insolvency risk. Severe and deteriorating unit economics with -$21M net loss and -$14M operating cash flow indicating fundamental business model failure.
What is BEATW's revenue and growth?
HeartBeam, Inc. reported revenue of N/A.
Does BEATW pay dividends?
HeartBeam, Inc. does not currently pay dividends.
Where can I find BEATW SEC filings?
Official SEC filings for HeartBeam, Inc. (CIK: 0001779372) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BEATW's EPS?
HeartBeam, Inc. has a diluted EPS of $-0.62.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.